Welkom bij Campus Sanofi Nederland
- Artikel
- Campus Sanofi
- 19 mrt 2024
Een platform voor beroepsbeoefenaren om betrouwbare en relevante informatie over onze medicijnen en therapieën te vinden.
InloggenWetenschappelijk nieuws
EVEREST study highlights
First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.
Bekijk meer
Understanding Disease Modification in Atopic Dermatitis
Understanding Disease Modification in Atopic Dermatitis
Bekijk meer
Act early, think holistically for your patients with Type 2 diabetes at very high cardiovascular risk
People with type 2 diabetes and atherosclerotic cardiovascular disease face a high risk of cardiovascular events, yet many remain undertreated.1 The EASD/ADA 2022 and ESC 2023 guidelines for the management of type 2 diabetes urge early insulin initiation and intensive lipid lowering through a holistic approach. Managing both glycemia and lipids together is key to preventing CV events in people with type 2 diabetes.2,3
Bekijk meer
